ARADIGM CORP Uncategorized Contracts & Agreements
31 Contracts & Agreements
- Bidding Procedures (Filed With SEC on March 9, 2020)
- AMENDMENT TO GOVERNANCEAGREEMENT (Filed With SEC on April 28, 2016)
- ATTACHMENT A (Filed With SEC on February 4, 2014)
- GOVERNANCE AGREEMENT by and between ARADIGM CORPORATION and GRIFOLS, S.A. Dated as of [ ], 2013 TABLE OF CONTENTS (Filed With SEC on May 24, 2013)
- ARADIGM CORPORATION (Filed With SEC on April 18, 2011)
- FINANCIAL STATEMENTS (Filed With SEC on November 6, 2009)
- FINANCIAL STATEMENTS (Filed With SEC on November 6, 2009)
- FINANCIAL STATEMENTS (Filed With SEC on November 6, 2009)
- FINANCIAL STATEMENTS (Filed With SEC on November 6, 2009)
- 4,000,000 Shares (Filed With SEC on February 26, 2009)
- 40,663,071 Shares (Filed With SEC on February 24, 2009)
- Current assets (Filed With SEC on November 12, 2008)
- Current assets (Filed With SEC on August 8, 2008)
- Current assets (Filed With SEC on August 8, 2008)
- Current assets (Filed With SEC on November 14, 2007)
- Current assets (Filed With SEC on November 14, 2007)
- AMENDMENT NO. 3 TO RIGHTS AGREEMENT BETWEEN ARADIGM CORPORATION AND COMPUTERSHARE TRUST COMPANY, N.A. (Filed With SEC on January 30, 2007)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on January 4, 2007)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on January 4, 2007)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- Current assets (Filed With SEC on August 14, 2006)
- In thousands, except shares data (Filed With SEC on November 15, 2004)
- Novo Nordisk A/S, the world leader in insulin products, for the needle-free delivery of insulin for diabetes; and (Filed With SEC on March 29, 2002)
- Novo Nordisk A/S, the world leader in insulin products, for the needle-free delivery of insulin for diabetes; and (Filed With SEC on March 29, 2002)
- EXHIBIT 10.15B (Filed With SEC on March 29, 2002)
- EXHBIIT 10.15A (Filed With SEC on March 29, 2002)
